樹突狀細胞聯合細胞因子誘導殺傷細胞治療晚期惡性腫瘤患者近期臨床療效觀察_West China Medical Journal

Authors：

 沈杰 ¹ , 劉濤 ¹ , 張丹 ¹ , 蘭大華 ¹ , 何鳳 ¹ , 盧斌 ²

1. ;
2. ;

Corresponding?author：

Keywords：

樹突狀細胞; 細胞因子誘導殺傷細胞; 晚期惡性腫瘤; 臨床觀察

DOI：

10.7507/1002-0179.20150026

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的觀察研究樹突狀細胞（DC）聯合細胞因子誘導殺傷細胞（CIK）協同治療晚期惡性腫瘤患者的近期臨床療效。方法采集2013年1月－6月104例晚期惡性腫瘤患者外周血單個核細胞進行DC、CIK細胞培養，7～14 d后回輸患者體內，觀察治療期不良反應癥狀及治療前后免疫指標、生活質量變化情況，并評估治療后病情緩解情況。結果治療期低熱5例，乏力3例，皮疹1例，無其他任何不良反應癥狀；治療后患者外周血中CD3⁺、CD4⁺及自然殺傷細胞百分比上升，CD8⁺細胞百分比下降，生活質量指標及Karnofsky功能狀態評分均有改善，差異有統計學意義（P＜0.05）；68例可測量病灶患者治療后部分緩解18例，穩定42例，進展8例，客觀緩解率為26.5%，疾病穩定率為88.2%。結論 DC/CIK細胞免疫治療在殺滅腫瘤細胞的同時，可以修復患者免疫系統，改善患者生活質量，且安全性高，不良反應小，可成為繼手術、放射治療、化學治療后晚期惡性腫瘤治療的重要手段。

Citation： 沈杰, 劉濤, 張丹, 蘭大華, 何鳳, 盧斌. 樹突狀細胞聯合細胞因子誘導殺傷細胞治療晚期惡性腫瘤患者近期臨床療效觀察. West China Medical Journal, 2015, 30(1): 97-99. doi: 10.7507/1002-0179.20150026 Copy

1.	He J, Gu D, Wu X, et al. Major causes of death among men and women in China[J]. N Engl J Med, 2005, 353(11):1124-1134.
2.	Hsu HS, Huang PI, Chang YL, et al. CucurbitacinⅠinhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung caner-derived CD133-positive cells[J]. Cancer, 2011, 117(13):2970-2985.
3.	鮑鋒, 盛春華, 楊光. DC-CIK細胞治療中晚期惡性腫瘤531例分析[J].中國免疫學雜志, 2011, 27(4):360-362.
4.	劉艷, 陳洪生, 劉明. DC、CIK細胞協同治療晚期惡性腫瘤的臨床觀察[J].實用腫瘤學雜志, 2011, 25(1):6-9.
5.	詹俊, 孫小娟, 李楚強, 等. S100和CD83陽性樹突狀細胞與大腸腫瘤微環境的關系[J].世界華人消化雜志, 2009, 17(29):3061-3065.
6.	Nagaraj S, Ziske C, Schmidt-Wolf IG. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transefer[J]. Genetic Vaccines and Ther, 2004, 2(1):12.
7.	Gao FG, Khammanivong V, Liu WJ, et al. Antigen-specific CD4(+) T-cell help is required to activate a memory CD8(+) T cell to a fully functional tumor killer cell[J]. Cancer Res, 2002, 62(22):6438-6441.
8.	Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells[J]. Anticancer Res, 2006, 26(3B):2237-2242.
9.	Li H, Yu JP, Cao S, et al. CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) Cells of lung cancer patients[J]. J Clin Immunol, 2007, 27(3):317-326.
10.	Zoll B, Lefterova P, Ebert O, et al. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation[J]. Cytokine, 2000, 12(9):1385-1390.
11.	Bryceson YT, Ljunggren HG. Tumor cell recognition by the NK cell activating receptor NKG2D[J]. Eur J Immunol, 2008, 38(11):2957-2961.
12.	匡志鵬, 梁安民. CIK細胞聯合樹突狀細胞治療惡性腫瘤的研究進展[J].現代腫瘤醫學, 2006, 14(2):240-242.
13.	M?rten A, Ziske C, Sch?ttker B, et al. Interactions between dendritic cells and cytokine-induced killer cells Lead to an activation of both populations[J]. J Immunother, 2001, 24(6):502-510.
14.	Wu J, Lu Y, Ding YB, et al. Promoter polymorphisms of IL2, IL4, and risk of gastric cancer in a high-risk Chinese population[J]. Mol Carcinog, 2009, 48(7):626-632.
15.	Horiuchi Y, Hanazawa A, Nakajima Y, et al. T-helper (Th)1/Th2 imbalance in the peripheral blood of dogs with malignant tumor[J]. Microbiol Immunol, 2007, 51(11):1135-1138.
16.	陳復興, 劉軍權, 張南征, 等.自身細胞因子誘導的殺傷細胞過繼性免疫治療惡性腫瘤的臨床觀察[J].癌癥, 2002, 21(7):797-801.
17.	李成文. IL-2治療的副作用[J].國外醫學:輸血及血液學分冊, 1997, 20(3):169-172.

1. He J, Gu D, Wu X, et al. Major causes of death among men and women in China[J]. N Engl J Med, 2005, 353(11):1124-1134.
2. Hsu HS, Huang PI, Chang YL, et al. CucurbitacinⅠinhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung caner-derived CD133-positive cells[J]. Cancer, 2011, 117(13):2970-2985.
3. 鮑鋒, 盛春華, 楊光. DC-CIK細胞治療中晚期惡性腫瘤531例分析[J].中國免疫學雜志, 2011, 27(4):360-362.
4. 劉艷, 陳洪生, 劉明. DC、CIK細胞協同治療晚期惡性腫瘤的臨床觀察[J].實用腫瘤學雜志, 2011, 25(1):6-9.
5. 詹俊, 孫小娟, 李楚強, 等. S100和CD83陽性樹突狀細胞與大腸腫瘤微環境的關系[J].世界華人消化雜志, 2009, 17(29):3061-3065.
6. Nagaraj S, Ziske C, Schmidt-Wolf IG. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transefer[J]. Genetic Vaccines and Ther, 2004, 2(1):12.
7. Gao FG, Khammanivong V, Liu WJ, et al. Antigen-specific CD4(+) T-cell help is required to activate a memory CD8(+) T cell to a fully functional tumor killer cell[J]. Cancer Res, 2002, 62(22):6438-6441.
8. Jiang J, Xu N, Wu C, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells[J]. Anticancer Res, 2006, 26(3B):2237-2242.
9. Li H, Yu JP, Cao S, et al. CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) Cells of lung cancer patients[J]. J Clin Immunol, 2007, 27(3):317-326.
10. Zoll B, Lefterova P, Ebert O, et al. Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation[J]. Cytokine, 2000, 12(9):1385-1390.
11. Bryceson YT, Ljunggren HG. Tumor cell recognition by the NK cell activating receptor NKG2D[J]. Eur J Immunol, 2008, 38(11):2957-2961.
12. 匡志鵬, 梁安民. CIK細胞聯合樹突狀細胞治療惡性腫瘤的研究進展[J].現代腫瘤醫學, 2006, 14(2):240-242.
13. M?rten A, Ziske C, Sch?ttker B, et al. Interactions between dendritic cells and cytokine-induced killer cells Lead to an activation of both populations[J]. J Immunother, 2001, 24(6):502-510.
14. Wu J, Lu Y, Ding YB, et al. Promoter polymorphisms of IL2, IL4, and risk of gastric cancer in a high-risk Chinese population[J]. Mol Carcinog, 2009, 48(7):626-632.
15. Horiuchi Y, Hanazawa A, Nakajima Y, et al. T-helper (Th)1/Th2 imbalance in the peripheral blood of dogs with malignant tumor[J]. Microbiol Immunol, 2007, 51(11):1135-1138.
16. 陳復興, 劉軍權, 張南征, 等.自身細胞因子誘導的殺傷細胞過繼性免疫治療惡性腫瘤的臨床觀察[J].癌癥, 2002, 21(7):797-801.
17. 李成文. IL-2治療的副作用[J].國外醫學:輸血及血液學分冊, 1997, 20(3):169-172.

Previous Article
Survey on the Antidepressant Use in In-patients with Depression

West China Medical Journal

樹突狀細胞聯合細胞因子誘導殺傷細胞治療晚期惡性腫瘤患者近期臨床療效觀察

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content